Synaptogenix (SNPX) 10-Q 5 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Entity File Number	001-40458
Entity Registrant Name	Synaptogenix, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-1585656
Entity Address, Address Line One	1185 Avenue of the Americas
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
City Area Code	973
Local Phone Number	242-0005
Entity Address, Postal Zip Code	10036
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	SNPX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Central Index Key	0001571934
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		6,840,629

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 28,754,621	$ 34,213,989
Prepaid Clinical trial expenses	280,820	410,357
Prepaid expenses and other current assets	523,034	879,869
TOTAL CURRENT ASSETS	29,558,475	35,504,215
Fixed assets, net of accumulated depreciation	20,777	20,445
TOTAL ASSETS	29,579,252	35,524,660
CURRENT LIABILITIES
Accounts payable	280,865	1,296,506
Accrued expenses	345,114	698,406
TOTAL CURRENT LIABILITIES	625,979	1,994,912
Commitments and contingencies
SHAREHOLDERS' EQUITY
Preferred stock - 1,000,000 shares authorized as of June 30, 2022, $0.0001 par value; 0 shares issued and outstanding as of June 30, 2022 and December 31, 2021
Common stock - 150,000,000 shares authorized as of March 31, 2022, $0.0001 par value; 6,810,326 shares issued and outstanding as of June 30, 2022 and 6,730,180 shares issued and outstanding as of December 31, 2021.	682	674
Additional paid-in capital	50,124,087	47,670,744
Accumulated deficit	(21,171,496)	(14,141,670)
TOTAL SHAREHOLDERS' EQUITY	28,953,273	33,529,748
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 29,579,252	$ 35,524,660

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Condensed Balance Sheets
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, shares authorized	150,000,000	150,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	6,810,326	6,730,180
Common stock, shares outstanding	6,810,326	6,730,180

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
OPERATING EXPENSES:
Research and development	$ 1,941,101	$ 986,280	$ 3,427,175	$ 2,138,060
General and administrative	1,855,290	1,308,893	3,651,748	3,312,306
TOTAL OPERATING EXPENSES	3,796,391	2,295,173	7,078,923	5,450,366
OTHER INCOME (EXPENSE):
Interest income	44,487	1,331	49,097	2,147
Net loss before income taxes	3,751,904	2,293,842	7,029,826	5,448,219
Provision for income taxes	0	0	0	0
Net loss attributable to common shareholders	$ 3,751,904	$ 2,293,842	$ 7,029,826	$ 5,448,219
PER SHARE DATA:
Basic loss per common share	$ 0.54	$ 0.58	$ 1.01	$ 1.53
Diluted loss per common share	$ 0.54	$ 0.58	$ 1.01	$ 1.53
Basic weighted average common shares outstanding	6,959,400	3,971,200	6,949,400	3,551,600
Diluted weighted average common shares outstanding	6,959,400	3,971,200	6,949,400	3,551,600

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders Equity - USD ($)	Common stock	Preferred stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance, Beginning at Dec. 31, 2020	$ 126	$ 0	$ 6,668,859	$ (1,530,473)	$ 5,138,512
Balance, Beginning (in shares) at Dec. 31, 2020	1,257,579	0
Stock based compensation	$ 0	$ 0	719,791	0	719,791
Issuance of warrants for consulting fees	0	0	396,848	0	396,848
Issuance of common stock for consulting fees	$ 0	$ 0	18,156		18,156
Issuance of common stock for consulting fees (in shares)	2,590	0
Exercise of common stock warrants	$ 94	$ 0	7,582,182	0	7,582,276
Exercise of common stock warrants (in shares)	941,394	0
Reverse stock split rounding	$ 0	$ 0	(1,529)	0	(1,529)
Reverse stock split rounding (in shares)	(345)	0
Private placement of common stock and warrants	$ 384	$ 0	23,783,777	0	23,784,161
Private placement of common stock and warrants (in shares)	3,837,580	0
Net loss	$ 0	$ 0	0	(5,448,219)	(5,448,219)
Balance, Ending at Jun. 30, 2021	$ 604	$ 0	39,168,084	(6,978,692)	32,189,996
Balance, Ending (in shares) at Jun. 30, 2021	6,038,798	0
Balance, Beginning at Mar. 31, 2021	$ 351		20,093,707	(4,684,850)	15,409,208
Balance, Beginning (in shares) at Mar. 31, 2021	3,508,129
Stock based compensation			151,552		151,552
Issuance of warrants for consulting fees			52,681		52,681
Issuance of common stock for consulting fees			18,156		18,156
Issuance of common stock for consulting fees (in shares)	2,590
Exercise of common stock warrants	$ 94		7,582,182		7,582,276
Exercise of common stock warrants (in shares)	941,394
Reverse stock split rounding			(1,529)		(1,529)
Reverse stock split rounding (in shares)	(345)
Private placement of common stock and warrants	$ 159		11,271,335		11,271,494
Private placement of common stock and warrants (in shares)	1,587,030
Net loss				(2,293,842)	(2,293,842)
Balance, Ending at Jun. 30, 2021	$ 604	$ 0	39,168,084	(6,978,692)	32,189,996
Balance, Ending (in shares) at Jun. 30, 2021	6,038,798	0
Balance, Beginning at Dec. 31, 2021	$ 674	$ 0	47,670,744	(14,141,670)	33,529,748
Balance, Beginning (in shares) at Dec. 31, 2021	6,730,180	0
Stock based compensation	$ 0	$ 0	1,728,248	0	1,728,248
Issuance of warrants for consulting fees	0	0	71,603	0	71,603
Issuance of common stock for consulting fees	$ 1	$ 0	100,349	0	100,350
Issuance of common stock for consulting fees (in shares)	15,146	0
Exercise of common stock warrants	$ 7	$ 0	553,143	0	553,150
Exercise of common stock warrants (in shares)	65,000
Net loss	$ 0	0	0	(7,029,826)	(7,029,826)
Balance, Ending at Jun. 30, 2022	$ 682	$ 0	50,124,087	(21,171,496)	28,953,273
Balance, Ending (in shares) at Jun. 30, 2022	6,810,326	0
Balance, Beginning at Mar. 31, 2022	$ 682		49,102,898	(17,419,592)	31,683,988
Balance, Beginning (in shares) at Mar. 31, 2022	6,809,647
Stock based compensation			1,016,690		1,016,690
Issuance of common stock for consulting fees			4,499		4,499
Issuance of common stock for consulting fees (in shares)	679
Net loss				(3,751,904)	(3,751,904)
Balance, Ending at Jun. 30, 2022	$ 682	$ 0	$ 50,124,087	$ (21,171,496)	$ 28,953,273
Balance, Ending (in shares) at Jun. 30, 2022	6,810,326	0

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOW USED IN OPERATING ACTIVITIES
Net loss	$ (7,029,826)	$ (5,448,219)
Adjustments to reconcile net loss to net cash used by operating activities
Stock based compensation	1,728,248	719,791
Consulting services paid by issuance of common stock	100,349	18,156
Consulting services paid by issuance of common stock warrants	71,603	396,848
Depreciation expense	2,697	2,487
Change in assets and liabilities
Decrease (Increase) in prepaid expenses	486,372	(431,869)
(Increase) in accounts payable	(1,015,640)	(612,171)
(Increase) in accrued expenses	(353,292)	(230,345)
Total adjustments	1,020,337	(137,103)
Net Cash Used in Operating Activities	(6,009,489)	(5,585,322)
CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of fixed assets	(3,029)
Net Cash Used in Investing Activities	(3,029)
CASH FLOWS FROM FINANCING ACTIVITIES
Private placements of common stock and warrants		23,784,161
Proceeds from exercise of investor warrants	553,150	7,582,276
Grant funding received		127,445
Cash in lieu of shares for reverse stock split		(1,529)
Net Cash Provided by Financing Activities	553,150	31,492,353
NET (DECREASE) INCREASE IN CASH AND EQUIVALENTS	(5,459,368)	25,907,031
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD	34,213,989	5,795,055
CASH AND EQUIVALENTS AT END OF PERIOD	$ 28,754,621	$ 31,702,086

Organization, Business, Risks a

Organization, Business, Risks and Uncertainties	6 Months Ended
	Jun. 30, 2022
Organization, Business, Risks and Uncertainties
Organization, Business, Risks and Uncertainties	Note 1 – Organization, Business, Risks and Uncertainties: Organization and Business On May 17, 2020, Neurotrope, Inc. (“Neurotrope” or “the Parent”) announced plans for the complete legal and structural separation of its wholly owned subsidiary, Neurotrope Bioscience, Inc., from Neurotrope (the “Spin-Off”). Under the Separation and Distribution Agreement, Neurotrope planned to distribute all of its equity interest in this wholly owned subsidiary to Neurotrope’s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in the Company, and the Company operates independently from Neurotrope. On December 7, 2020, the Company became an independent company, Synaptogenix, Inc., a Delaware corporation (formerly known as Neurotrope Bioscience, Inc.) (the “Company” or “Synaptogenix”) when the Company filed an amended and restated certificate of incorporation which, among other things, changed its name to Synaptogenix, Inc. The Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), are listed on The Nasdaq Capital Market under the symbol “SNPX.” Neurotrope Bioscience, Inc. was incorporated in Delaware on October 31, 2012 to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). The Company is collaborating with Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February 28, 2013 (see Note 4 - Related Party Transactions and Licensing / Research Agreements). In connection with the separation from Neurotrope, we entered into a Separation and Distribution Agreement and several other ancillary agreements. These agreements govern the relationship between the parties after the separation and allocate between the parties’ various assets, liabilities, rights and obligations following the separation, including employee benefits, intellectual property, information technology, insurance and tax-related liabilities. Liquidity Uncertainties As of June 30, 2022, the Company had approximately $28.8 million in cash and cash equivalents as compared to $34.2 million at December 31, 2021. The Company expects that its current cash and cash equivalents, approximately $27.4 million as of the date of this quarterly report, will be sufficient to support its projected operating requirements for at least the next 12 months from this date. The operating requirements include the current development plans for Bryostatin-1, our novel drug candidate targeting the activation of Protein Kinase C Epsilon and other development projects. The Company expects to need additional capital in order to initiate and pursue potential additional development projects, including the continuing development beyond the ongoing Phase 2 trial of Bryostatin-1. Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders, and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on our business, financial condition and results of operations. Other Risks and Uncertainties The Company operates in an industry that is subject to rapid technological change, intense competition, and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological and regulatory. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the limited supply of raw materials, the ability to obtain favorable licensing, manufacturing or other agreements, including risk associated with our CRE licensing agreement, and the ability to raise capital to achieve strategic objectives. CRE has entered into a material transfer agreement with the National Cancer Institute of the National Institutes of Health (“NCI”), pursuant to which the NCI has agreed to supply bryostatin required for the Company’s pre-clinical research and clinical trials. This agreement does not provide for a sufficient amount of bryostatin to support the completion of all of the clinical trials that the Company is required to conduct in order to seek U.S. Food and Drug Administration (“FDA”) approval. Therefore, CRE or the Company would have to enter into one or more subsequent agreements with the NCI for the supply of additional amounts of bryostatin. If CRE or the Company were unable to secure such additional agreements, or if the NCI otherwise discontinues the supply, the Company would have to either secure another source of bryostatin or discontinue its efforts to develop and commercialize Bryostatin-1 for the treatment of AD. In June 2020, the Company entered into a supply agreement (the “Supply Agreement”) with BryoLogyx Inc. (“BryoLogyx”), pursuant to which BryoLogyx agreed to be the Company’s exclusive supplier of synthetic bryostatin. Pursuant to the terms of the Supply Agreement, the Company received its initial order of one gram synthetic bryostatin. See Note 3. The Company also faces the ongoing risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company’s trial. In order to prioritize patient health and that of the investigators at clinical trial sites, we will monitor enrollment of new patients in our current Phase 2 clinical trial. In addition, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. These and other factors outside of our control could delay our ability to conduct clinical trials or release clinical trial results. In addition, the effects of a pandemic resurgence may also increase non-trial costs such as insurance premiums, increase the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key clinical trial vendors and suppliers.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies: Basis of Presentation: The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the unaudited condensed financial statements included herein contain all adjustments necessary to present fairly the Company’s financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2022 may not be indicative of results for the full year. These unaudited condensed financial statements should be read in conjunction with the audited condensed financial statements and the notes to those statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2022. ​ Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management’s best judgment at a point in time and as such these estimates may ultimately differ from actual results. ​ Cash and Cash Equivalents and Concentration of Credit Risk: The Company considers all highly liquid cash investments with an original maturity of three months or less when purchased to be cash equivalents. At June 30, 2022, the Company’s cash balances that exceed the current insured amounts under the Federal Deposit Insurance Corporation (“FDIC”) were approximately $1.0 million. In addition, approximately $27.6 million included in cash and cash equivalents were invested in a money market fund, which is not insured under the FDIC. ​ Fixed Assets: ​ Fixed assets are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the estimated useful life of the asset, which is deemed to be between three Research and Development Costs: All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE are expensed when incurred. Non-refundable advance payments for research and development are capitalized because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services, other than non-refundable advance payments as mentioned below for Worldwide Clinical Trials, at June 30, 2022 and December 31, 2021. Income Taxes: The Company accounts for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes under the “Separate return method.” Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions for accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company has determined that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is generally three years from the date of filing. The Company had federal and state net operating loss carryforwards for income tax purposes of approximately $84.4 million for the period from October 31, 2012 (inception) through June 30, 2022. The net operating loss carryforwards resulted in a deferred tax asset of approximately $17.7 million at June 30, 2022. Income tax effects of share-based payments are recognized in the financial statements for those awards that will normally result in tax deductions under existing tax law. The deferred tax asset is offset by a full valuation allowance. The Company may be subject to significant U.S. federal income tax-related liabilities with respect to the Spin-Off if there is a determination that the Spin-Off is taxable for U.S. federal income tax purposes. In connection with the Spin-Off, the Company believes that, among other things, the Spin-Off should qualify as a tax-free transaction for U.S. federal income tax purposes under Section 355 and Section 368(a)(1)(D) of the Internal Revenue Code of 1986 (the “Code”). If the conclusions of the tax opinions are not correct, or if the Spin-Off is otherwise ultimately determined to be a taxable transaction, the Company would be liable for U.S. federal income tax related liabilities. Pursuant to the Separation and Distribution Agreement and the Tax Matters Agreement, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix’s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses. At June 30, 2022 and as of the date of financial statement issuance date, the Company does not have any indemnification liabilities. Under Section 382 of the Code, as amended, changes in the Company’s ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. In addition, the significant historical operating losses incurred by the Company may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. The Company believes that operating loss carryforwards are limited under Section 382 limitations although Section 382 studies have not been conducted to determine the actual limitations. ​ Expense Reimbursement for Grant Award: The Company reduces its research and development expenses by funding received or receivable from an NIH grant during the period that the expenses are incurred. The Company recognized grant related expense reductions during the three and six months ended June 30, 2022 of approximately $100,000 and $0, respectively, and $0 for the three and six months ended June 30, 2021, respectively. See Note 5, “ Clinical Trial Services Agreements Of the total $2.7 million available from the NIH grant, the Company has received the maximum reimbursements under the grant as of June 30, 2022. Recent Accounting Pronouncements: In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, which reduces the number of accounting models for convertible instruments, amends diluted earnings per share calculations for convertible instruments and allows more contracts to qualify for equity classification. ASU 2020-06 will be effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted. The Company has evaluated the adoption of ASU 2020-06 and has concluded that it does not apply at this time. ​

Collaborative Agreements and Co

Collaborative Agreements and Commitments	6 Months Ended
	Jun. 30, 2022
Collaborative Agreements and Commitments
Collaborative Agreements and Commitments	Note 3– Collaborative Agreements and Commitments: ​ Stanford License Agreements On May 12, 2014, the Company entered into a license agreement (the “Stanford Agreement”) with The Board of Trustees of The Leland Stanford Junior University (“Stanford”), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. The Company is required to use commercially reasonable efforts to develop, manufacture and sell products (“Licensed Products”) in the Licensed Field of Use (as defined in the Stanford Agreement) during the term of the licensing agreement which expires upon the termination of the last valid claim of any licensed patent under this agreement. In addition, the Company must meet specific product development milestones, and upon meeting such milestones, make specific milestone payments to Stanford. The Company must also pay Stanford royalties of 3% of net sales, if any, of Licensed Products (as defined in the Stanford Agreement) and milestone payments of up to $3.7 million dependent upon stage of product development. As of June 30, 2022, no royalties nor milestone payments have been required. On January 19, 2017, the Company entered into a second license agreement with Stanford, pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of “Bryostatin Compounds and Methods of Preparing the Same,” or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents. The Company paid Stanford $70,000 upon executing the license and is obligated to pay an additional $10,000 annually as a license maintenance fee. In addition, based upon certain milestones that include product development and commercialization, the Company will be obligated to pay up to an additional $2.1 million and between 1.5% and 4.5% royalty payments on certain revenues generated by the Company relating to the licensed technology. On November 9, 2021, the Company revised the existing licensing agreement with Stanford. The revisions extended all the required future product development and commercialization milestones. The Company is currently in full compliance with the revised agreement and is moving forward on its commitments. As of the end of the period covered by this quarterly report, no royalties nor milestone payments have been earned or made. Mt. Sinai License Agreement On July 14, 2014, the Company entered into an Exclusive License Agreement (the “Mount Sinai Agreement”) with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Pursuant to the Mount Sinai Agreement, Mount Sinai granted the Company (a) a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai’s interest in certain joint patents held by the Company and Mount Sinai (the “Joint Patents”) as well as in certain results and data (the “Data Package”) and (b) a non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of Protein Kinase C Epsilon (“PKC ε”), which includes Niemann-Pick Disease (the “Mount Sinai Field of Use”). The Mount Sinai Agreement allows the Company to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai’s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (“Mount Sinai Licensed Products”) in the Mount Sinai Field of Use (as such terms are defined in the Mount Sinai Agreement). The Company is required to pay Mt. Sinai milestone payments of $2.0 million upon approval of a new drug applications (“NDA”) in the United States and an additional $1.5 million for an NDA approval in the European Union or Japan. In addition, the Company is required to pay Mt. Sinai royalties on net sales of licensed product of 2.0% for up to $250 million of net sales and 3.0% of net sales over $250 million. Since inception, the Company has paid Mt. Sinai approximately $180,000 consisting of licensing fees of $105,000 plus development costs and patent fees of approximately $75,000. As of June 30, 2022, no royalties nor milestone payments have been required. Agreements with BryoLogyx On June 9, 2020, the Company entered into a supply agreement (the “Supply Agreement”) with BryoLogyx Inc. (“BryoLogyx”), pursuant to which BryoLogyx agreed to serve as the Company’s exclusive supplier of synthetic bryostatin. Pursuant to the terms of the Supply Agreement, the Company placed an initial order and subsequently received one gram of current good manufacturing practice (“cGMP”) synthetic bryostatin as an active pharmaceutical ingredient to be used in a drug product (“API”). The Company may place additional orders for API beyond the initial order by making a written request to BryoLogyx no later than six months prior to the requested delivery date. The Company is not currently using synthetic bryostatin for its current Phase 2 clinical trial and will determine when to incorporate the synthetic into the clinical trial process. In connection with the Supply Agreement, on June 9, 2020, the Company entered into a transfer agreement (the “Transfer Agreement”) with BryoLogyx. Pursuant to the terms of the Transfer Agreement, the Company agreed to assign and transfer to BryoLogyx all of the Company’s right, title and interest in and to that certain Cooperative Research and Development Agreement, dated as of January 29, 2019 (the “CRADA”), by and between the Company and the U.S. Department of Health and Human Services, as represented by the NCI, under which Bryostatin-1’s ability to modulate CD22 in patients with relapsed/refractory CD22+ disease has been evaluated to date. Pursuant to guidance provided by NCI, the Company CRADA has been cancelled and BryoLogyx has initiated a request for a new CRADA in its name. BryoLogyx will be filing its own investigational new drug application (“IND”) for CD22 with the FDA. As consideration for the transfer of rights to the CRADA, BryoLogyx has agreed to pay to the Company 2% of the gross revenue received in connection with the sale of bryostatin products, up to an aggregate payment amount of $1 million. No such revenues have been earned as of June 30, 2022. Nemours Agreement On September 5, 2018, we announced a collaboration with Nemours A.I. DuPont Hospital (“Nemours”), a premier U.S. children’s hospital, to initiate a clinical trial in children with Fragile X syndrome, a genetic disorder. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior. On August 5, 2021, the Company announced its memorandum of understanding with Nemours to initiate a clinical trial using Bryostatin-1, under Orphan Drug Status, to treat Fragile X. The Company intends to provide the Bryostatin-1 and obtain the investigational new drug documentation (“IND”) and Nemours intends to provide the clinical site and attendant support for the trial. The Company and Nemours, jointly, will develop the trial protocol. The Company estimates its total trial and IND cost to be approximately $700,000. As of the end of the period covered by this quarterly report, the Company has not incurred any expenses associated with this agreement. ​ Cleveland Clinic On February 23, 2022, the Company announced its collaboration with the Cleveland Clinic to pursue possible treatments for Multiple Sclerosis. The collaboration entails filing an IND and conducting initial clinical trials using Bryostatin-1. Future development work will be conducted pursuant to statements of work to be determined. Cognitive Research Enterprises, Inc. (“CRE”) Effective October 31, 2012, the Company executed a Technology License and Services Agreement (the “TLSA”) with CRE, a related party, and NRV II, LLC (“NRV II”), another affiliate of CRE, which was amended by Amendment No. 1 to the TLSA as of August 21, 2013, as amended and restated on February 4, 2015 (the “CRE License Agreement”). The CRE License Agreement provides research services and has granted the Company the exclusive and nontransferable world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under CRE’s and NRV II’s respective right, title and interest in and to certain patents and technology owned by CRE or licensed to NRV II by CRE as of or subsequent to October 31, 2012, to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic applications for AD and other cognitive dysfunctions in humans or animals (the “Field of Use”). Additionally, the CRE License Agreement specifies that all patents that issue from a certain patent application shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the CRE License. The CRE License Agreement terminates on the later of the date (a) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b) the last of the intellectual property enters the public domain. After Neurotrope’s initial Series A Stock financing, the CRE License Agreement required the Company to enter into scope of work agreements with CRE as the preferred service provider for any research and development services or other related scientific assistance and support services. There were no such statements of work agreements entered into during the years ended December 31, 2021 and 2020, respectively, or during the three and six months ended June 30, 2022. In addition, on November 10, 2018, the Company and CRE entered into a second amendment (the “Second Amendment”) to the TLSA pursuant to which CRE granted certain patent prosecution and maintenance rights to the Company. Under the Second Amendment, the Company will have the sole and exclusive right and the obligation, to apply for, file, prosecute and maintain patents and applications for the intellectual property licensed to the Company, and pay all fees, costs and expenses related to the licensed intellectual property.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions
Related Party Transactions	Note 4- Related Party Transactions: Related Party Agreements On August 4, 2016, Neurotrope, Inc. entered into a consulting agreement with SM Capital Management, LLC (“SMCM”), a limited liability company owned and controlled by the Company’s Chairman of the Board, Mr. Joshua N. Silverman (the “Consulting Agreement”). Pursuant to the Consulting Agreement, SMCM shall provide consulting services which shall include, but not be limited to, providing business development, financial communications and management transition services, for a one-year period, subject to annual review thereafter. SMCM’s annual consulting fee is $120,000, payable by the Company in monthly installments of $10,000. This contract was assigned to Synaptogenix, Inc. as of December 1, 2020. For the three and six months ended June 30, 2022 and 2021, $30,000 and $60,000 is reflected in the Company’s statements of operations, respectively.

Other Commitments_

Other Commitments:	6 Months Ended
	Jun. 30, 2022
Other Commitments:
Other Commitments:	Note 5 – Other Commitments: Clinical Trial Services Agreements On July 23, 2020, the Company entered into the 2020 Services Agreement with Worldwide Clinical Trials, Inc. (“WCT”). The 2020 Services Agreement relates to services for the current Phase 2 clinical trial assessing the safety, tolerability and long-term efficacy of Bryostatin-1 in the treatment of moderately severe AD subjects not receiving memantine treatment (the “2020 Study”). Pursuant to the terms of the 2020 Services Agreement, WCT is providing services to enroll approximately one The Company was awarded a $2.7 million grant from the NIH, which will be used to support the 2020 Study, resulting in an estimated net budgeted cost of the 2020 Study to the Company of $9.3 million. The NIH grant provides for funds in the first year, which began in April 2020, of approximately $1.0 million and funding in year two, which began April 2021, of approximately $1.7 million. As of February 22, 2022, virtually all of the NIH grant has been received and offset against the clinical trial costs. The Company incurred approximately $9.4 million of cumulative expenses associated with the current Phase 2 clinical trial as of June 30, 2022. Of the total $9.4 million incurred for the trial to date, approximately $1.2 million and $2.5 million is reflected in the statement of operations for the three and six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022 included in the Company’s balance sheet, approximately $281,000 of WCT prepayments is included as a prepaid expense and other current assets. In addition, approximately $414,000 is included in accounts payable and accrued expenses. On May 12, 2022, the Company entered into the 2022 Services Agreement with WCT. The 2022 Services Agreement relates to services for a Phase 2 “open label,” dose ranging study, clinical trial assessing the safety, tolerability and efficacy of Bryostatin-1 administered via infusion in the treatment of moderately severe to severe AD subjects not receiving memantine treatment (the “2022 Study”). Pursuant to the terms of the 2022 Services Agreement, WCT is providing services to enroll approximately 12 2022 Study subjects, which enrollment is currently underway. The first 2022 Study site was initiated during the third quarter of 2022. The total estimated budget for the services, including pass-through costs, is currently approximately $2.0 million. Either party may terminate the 2022 Services Agreement without cause upon [ninety] days prior written notice. Furthermore, in the event of a material breach by the other party, which breach is not cured by the breaching party, the other party may terminate the agreement upon 30 days’ prior written notice. On January 19, 2022, the Company issued a work order (the “Work Order”) to Cyprotex US, LLC (“Cyprotex”), pursuant to which Cyprotex will perform certain drug interaction services for the Company for an aggregate fee of $165,455. The Work Order is governed by the Cyprotex’s Standard Terms and Conditions for Discovery Services dated August 2, 2021. The Company incurred approximately $169,000 and $177,000 for this Work Order for the three and six months ended June 30, 2022, respectively. On January 31, 2022, the Company entered into a Statement of Work (the “SOW”) with Charles River Laboratories, Inc. (“Charles River”). The Statement of Work is subject to the General Terms and Conditions of Charles River. Pursuant to the SOW, Charles River will conduct a certain pre-clinical animal study (the “Study”) relating to Bryostatin-1 pharmacodynamics and drug distribution, for an initial aggregate fee of $197,600. Either party may terminate the 2022 Services Agreement without cause upon ninety days prior written notice. Furthermore, in the event of a material breach by the other party, which breach is not cured by the breaching party, the other party may terminate the agreement upon 30 days’ prior written notice. The Company has not incurred any expense relating to this SOW as of June 30, 2022. Other Consulting Agreements Effective as of June 1, 2019, the Company entered into a consulting agreement with Katalyst Securities LLC (“Katalyst”), pursuant to which Katalyst provided investment banking consulting services to the Company and Neurotrope (the “Katalyst Agreement”). The term of the Katalyst Agreement continued until it was canceled. As consideration for its services under the Katalyst Agreement, the Company paid Katalyst $25,000 per month thru December 1, 2020, plus five-year warrants to purchase 4,500 shares of Neurotrope’s common stock on the effective date of the Katalyst Agreement and on each of the three-month anniversaries following the effective date with the last issuance on December 1, 2020. Effective as of January 1, 2021, the Company entered into an amended consulting agreement with Katalyst reducing the cash payment to $20,000 per month. Effective as of January 1, 2022, the Company entered into an additional amended consulting agreement with Katalyst reducing the cash payment to $10,000 per month beginning February 1, 2022 thru December 31, 2022 and eliminating any further warrant issuances. In addition, on February 16, 2021, Katalyst was granted warrants to purchase 25,000 shares of Common Stock at $11.46 per share, on April 1, 2021, was granted warrants to purchase an additional 4,500 shares of Common Stock at $8.80 per share, on July 1, 2021, was granted warrants to purchase an additional 4,500 shares of Common Stock at $9.76 per share, on October 1, 2021, was granted warrants to purchase an additional 4,500 shares of Common Stock at $9.30 per share, and, on January 3, 2022, was granted warrants to purchase an additional 4,500 shares of Common Stock at $8.69 per share. Each of the warrants issued to Katalyst are exercisable for a period of five years from the date of issuance. For the three months ended June 30, 2022 and 2021, $30,000 and $93,687 is reflected in the Company’s statements of operations, respectively, and $111,283 and $399,700 is reflected in the Company’s statements of operations for the six months ended June 30, 2022 and 2021, respectively, pursuant to the consulting agreement. Effective as of June 5, 2019, the Company entered into a consulting agreement with GP Nurmenkari, Inc. (“GPN”) (the “GPN Agreement”), pursuant to which GPN agreed to provide investment banking consulting services to the Company and Neurotrope. The term of the agreement continued until December 1, 2020. On February 1, 2020, the Company amended the GPN Agreement, increasing the cash compensation to $17,500 per month thru November 30, 2020 and increasing the number of warrants issued each three-month period to 2,500, with the last issuance on December 1, 2020. Effective as of January 1, 2021, the Company entered into an amended consulting agreement with GPN reducing the cash payment to $12,000 per month. Effective as of July 1, 2021, the Company entered into a second amended consulting agreement with GPN increasing the cash payment to $20,000 per month and increasing warrant issued for each three-month period beginning July 1, 2021 to 5,800, with the last issuance on October 1, 2021. Effective as of January 1, 2022, the Company entered into an additional amended consulting agreement with GPN reducing the cash payment to $10,000 per month beginning February 1, 2022 thru December 31, 2022 and eliminating any further warrant issuances. In addition, on February 16, 2021, GPN was granted warrants to purchase 10,000 shares of Common Stock at $11.46 per share, on April 1, 2021, was granted warrants to purchase an additional 2,500 shares of Common Stock at $8.80 per share, on July 1, 2021, was granted warrants to purchase an additional 5,800 shares of Common Stock at $9.76 per share, on October 1, 2021, was granted warrants to purchase an additional 5,800 shares of Common Stock at $9.30 per share, and, on January 3, 2022, was granted warrants to purchase an additional 5,800 shares of Common Stock at $8.69 per share. Each of the warrants issued to GPN are exercisable for a period of five years from the date of issuance. For the three months ended June 30, 2022 and 2021, $30,000 and $54,815 is reflected in the Company’s statements of operations, and $120,320 and $189,148 is reflected in the Company’s statements of operations for the six months ended June 30, 2022 and 2021, respectively, pursuant to the GPN Agreement. Employment Agreements On December 7, 2020, the Company entered into an offer letter (the “Offer Letter”) with Alan J. Tuchman, M.D., pursuant to which Dr. Tuchman agreed to serve as the Company’s Chief Executive Officer, commencing on December 7, 2020. In addition, in connection with his appointment as the Company’s Chief Executive Officer, Dr. Tuchman was appointed to the board of directors of the Company. Dr. Tuchman will receive an initial annual base salary of $222,000, with an annual discretionary bonus of up to 50% of his base salary then in effect. Dr. Tuchman also received an initial equity grant (subject to Board approval which was received in January 2021) of options to purchase a number of shares of Common Stock equal to at least 1% of the Company’s outstanding shares of Common Stock immediately following the Spin-Off. As of December 7, 2021, such options are fully vested. The term of Dr. Tuchman’s employment pursuant to the Offer Letter is one year, which shall be extended automatically for six month periods unless either party gives timely written notice. Dr. Tuchman’s agreement was previously extended until December 7, 2022. On August 4, 2022, the Company entered into an amendment to the Offer Letter to extend the term of Dr. Tuchman’s employment through June 7, 2023, and such term shall be extended for an additional six months upon Dr. Tuchman’s written notice to the Company at least 30 days prior to June 7, 2023. Pursuant to the Amendment, if Dr. Tuchman is terminated without Cause, Dr. Tuchman shall be entitled to severance equal to six months of Dr. Tuchman’s annual base salary. Other Commitments and Agreements See Notes 3 and 4 for Collaboration and License Agreement related commitments. Pursuant to the Separation Agreement and Tax Matters Agreement with Neurotrope, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix’s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses ourselves. As of the reporting date, there are no claims relating to the indemnification agreement.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity
Stockholders' Equity	Note 6 – Stockholders’ Equity: The Company’s certificate of incorporation authorizes it to issue 150,000,000 shares of Common Stock and 1,000,000 shares of preferred stock, par value $0.0001 per share. The holders of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends at such times and in such amounts as the Board from time to time may determine. To date, the Company has not paid dividends on its Common Stock. Holders of Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting of the election of directors then standing for election. The Common Stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon liquidation, dissolution or winding up of the Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of Common Stock after payment of liabilities, accrued dividends and liquidation preferences, if any. Each outstanding share of Common Stock is duly and validly issued, fully paid and non-assessable. ​ January 2021 Private Placement ​ On January 21, 2021, the Company entered into Securities Purchase Agreements (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”) to issue (a) an aggregate of 2,333,884 shares of Common Stock and/or prefunded warrants to purchase shares of Common Stock at an exercise price of $0.04 per share (the “Pre-Funded Warrants”), (b) Series E warrants to purchase 2,333,908 shares of Common Stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of twelve months from the date of an effective registration statement (the “Series E Warrants”) and (c) Series F warrants to purchase up to an aggregate of 2,333,908 shares of Common stock, with an exercise price of $6.90 per share (subject to adjustment), for a period of five years from the date of issuance (the “Series F Warrants” and together with the Series E Warrants, the “Warrants”) at a combined purchase price of $6.00 per share of Common Stock and Warrants (the “Offering”). The Company received total gross proceeds of approximately $14,000,000 and net proceeds of approximately $12.5 million. In connection with the Offering, we paid our placement agents Katalyst and GPN (i) a cash fee equal to ten percent (10%) of the gross proceeds from any sale of securities in the Offering sold to Purchasers introduced by the Placement Agent and (ii) 233,391 warrants to purchase 233,391 shares of Common Stock (equal to ten percent (10%) of the number of shares of Common Stock sold to Purchasers introduced by the placement agents), with an exercise price of $6.90 per share and a five-year term. June 2021 Private Placement On June 14, 2021, the Company entered into Securities Purchase Agreements (the “June Purchase Agreement”) with certain accredited investors (the “June Purchasers”) to issue (a) an aggregate of 1,653,281 shares of the Company’s Common Stock and/or prefunded warrants to purchase shares of Common Stock at an exercise price of $0.01 per share (the “June Pre-Funded Warrants”) and (b) Series G warrants to purchase up to an aggregate of 1,653,281 shares of Common stock, with an exercise price of $8.51 per share (subject to adjustment), for a period of five years from the date of issuance (the “June Warrants”) at a combined purchase price of $7.547 per share of Common Stock and June Warrant (the “June Offering”). The Company received total gross proceeds of approximately $12.5 million and net proceeds of approximately $11.2 million. In connection with the June Offering, pursuant to an Engagement Agreement, dated June 14, 2021 (the “June Engagement Agreement”), between the Company and Katalyst Securities LLC (the “June Placement Agent”), the Company paid the June Placement Agent (i) a cash fee equal to ten percent (10%) of the gross proceeds from the sale of securities in the June Offering sold to June Purchasers introduced by the June Placement Agent and (ii) 152,378 warrants to purchase 152,378 shares of Common Stock (equal to ten percent (10%) of the number of shares of Common Stock sold to June Purchasers introduced by the June Placement Agent), with an exercise price of $7.547 per share and a five-year term (the “June Broker Warrants”). Furthermore, the Company agreed to pay the June Placement Agent a warrant exercise fee equal to ten percent (10%) of the aggregate exercise price that is paid in connection with each exercise, if any, of the June Warrants initially held by June Purchasers introduced by the June Placement Agent. The total potential fee payable to the June Placement Agent if all Series G warrants are exercised is approximately $1.4 million. The June Placement Agent is also entitled to the foregoing fees with respect to any future financing or capital-raising transaction by the Company (a “Subsequent Financing”), to the extent such financing or capital is provided to the Company by investors whom the Placement Agent had introduced to the Company, in the event such Subsequent Financing is consummated within eighteen (18) months following the closing of the June Offering. Adoption of a Shareholder Rights Plan On January 13, 2021, the Company adopted a shareholder rights plan (the “Rights Plan”). The Rights Plan is intended to protect the interests of the Company’s stockholders and enable them to realize the full potential value of their investment by reducing the likelihood that any person or group gains control of the Company, through open market accumulation or other tactics, without appropriately compensating all stockholders. Pursuant to the Rights Plan, the Company will issue, by means of a dividend, one preferred share purchase right for each outstanding share of our Common Stock to shareholders of record on the close of business on January 25, 2021. Initially, these Rights will trade with, and be represented by, the shares of our Common Stock. The Rights will generally become exercisable only if any person (or any persons acting as a group) acquires 15% or more of our outstanding Common Stock (the “Acquiring Person”) in a transaction not approved by the Board, subject to certain exceptions, as explained below. If the Rights become exercisable, all holders of Rights, other than the Acquiring Person, will be entitled to acquire shares of Common Stock at a 50% discount or the Company may exchange each Right held by such holders for one share of Common Stock. In such situation, Rights held by the Acquiring Person would become void and will not be exercisable. If any person at the time of the first public announcement of the Rights Plan owns more than the triggering percentage, then that stockholder’s existing ownership percentage will be grandfathered, although, with certain exceptions, the Rights will become exercisable if at any time after the announcement of the Rights Plan such stockholder increases its ownership of Common Stock. On January 13, 2021, the board of directors of the Company (the “Board”)declared a dividend of one preferred share purchase right (a “Right”), payable on January 25, 2021, for each share of Common Stock outstanding on January 25, 2021 (the “Record Date”) to the stockholders of record on that date. In connection with the distribution of the Rights, the Company entered into a Rights Agreement (the “Rights Agreement”), dated as of January 19, 2021, between the Company and Philadelphia Stock Transfer, Inc., as rights agent. Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series A Preferred Stock, par value $0.001 per share (the “Preferred Shares”), of the Company at a price of $20 per one one-thousandth of a Preferred Share represented by a Right (the “Purchase Price”), subject to adjustment. Unless earlier redeemed, terminated or exchanged pursuant to the terms of the Rights Plan, the Rights will expire at the close of business on January 13, 2023. The Board may terminate the Rights Plan before that date if the Board determines that there is no longer a threat to shareholder value. Reverse Stock Split ​ At the Special Meeting (as defined below), the stockholders approved our proposal to effect one reverse stock split of the Company’s outstanding shares of Common stock, at any ratio between 1-for-1.5 and 1-for-20, at such time as the Company’s Board of Directors shall determine, in its sole discretion, before December 31, 2022. On May 19, 2021, the Company effected a 1-for-4 ​

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2022
Stock Based Compensation
Stock Based Compensation	Note 7 – Stock Based Compensation: 2020 Equity Incentive Plan Upon completion of the Spin-Off, the Company’s 2020 Equity Incentive Plan (the “2020 Plan”) became effective on December 7, 2020. The total number of securities available for grant under the 2020 Plan was 250,000 shares of Common Stock, subject to adjustment. On April 7, 2021, the Company held a special meeting of stockholders (“Special Meeting”) in which the Company’s stockholders approved an amendment to the Company’s 2020 Plan to increase the total number of shares of Common Stock from 250,000 to an aggregate of 625,000 shares of Common Stock. Stock and Option Grants ​ The following is a summary of stock option activity under the stock option plans for the six months ended June 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ Average ​ Aggregate ​ ​ ​ ​ Weighted- ​ Remaining ​ Intrinsic ​ ​ Number ​ Average ​ Contractual ​ Value ​ ​ of ​ Exercise ​ Term ​ (in ​ ​ Shares ​ Price ​ (Years) ​ millions) Options outstanding at January 1, 2022 123,850 ​ $ 9.84 9.00 ​ $ — Options granted 6,150 ​ $ 7.29 — ​ — Less options forfeited — ​ $ — — ​ — Less options expired/cancelled — ​ $ — — ​ — Less options exercised — ​ $ — — ​ — Options outstanding at June 30, 2022 130,000 ​ $ 9.72 8.60 ​ $ — Options exercisable at June 30, 2022 125,388 ​ $ 9.81 8.57 ​ $ — ​ As of June 30, 2022, the Company had unrecognized stock option expense of approximately $16,900 and a remaining weighted average period for recognition of 0.63 years. On February 16, 2022, pursuant to its 2020 Plan, the Company granted stock options to purchase an aggregate of 6,150 shares of Common Stock to its Chief Executive Officer. The stock options have an exercise price of $7.29 per share and an expiration date that is ten years from the date of issuance. 25% of the options vest each quarter over one year, with the initial 25% vesting on May 16, 2022. On March 12, 2021, Synaptogenix adopted a new non-employee director compensation policy (the “Director Compensation Policy”). The Director Compensation Policy provides for the annual automatic grant of nonqualified stock options to purchase up to 1,500 shares of Synaptogenix’s Common Stock to each of Synaptogenix’s nonemployee directors. Such grants shall occur annually on the fifth business day after the filing of Synaptogenix’s Annual Report on Form 10-K and shall vest on the one-year anniversary from the date of grant subject to the director’s continued service on the Board of Directors on the vesting date. The Director Compensation Policy also provides for the automatic grant of nonqualified stock options to purchase up to 1,200 shares of Synaptogenix’s Common Stock, plus options to purchase an additional 300 shares of Common Stock for service on a committee of the Board of Directors, to each newly appointed director following the date of his or her appointment. Such options shall vest as follows: fifty percent (50%) on the date of the grant, twenty-five percent (25%) on the one year anniversary from the date of the grant, and twenty-five percent (25%) on the second year anniversary from the date of the grant, subject to the director’s continued service on the Board of Directors on the applicable vesting dates. The Company recorded total expense relating to the outstanding stock options of $11,544 and $151,552 for the three months ended June 30, 2022 and 2021, respectively, and $47,918 and $719,791 for the six months ended June 30, 2022 and 2021. Restricted Stock Unit Grants On July 13, 2021, the Company granted a total of 495,000 restricted stock units (RSUs), of which 425,000 were granted to seven Board members (including two executives), 60,000 to the Company’s CFO and 10,000 to two employees. The RSUs were amended on January 12, 2022 to vest 100% on September 15, 2022 and then further amended on June 20, 2022 to vest 100% on the earlier of release of Phase 2 clinical trial top line data or December 31, 2022. Top line data is expected to be announced during the fourth quarter of 2022. As of June 30, 2022, the Company had unrecognized RSUs expense of approximately $885,000 and a remaining weighted average period for recognition of 0.44 years. The fair value of the RSUs issued was based upon the closing trading price of the Common Stock on the grant date of $9.75 per share. The grant date fair value of the RSUs granted was approximately $4.8 million. The Company recorded total expense of $1,005,146 and $1,680,331 relating to the outstanding RSUs for the three and six months ended June 30, 2022, respectively. ​ Restricted Stock Issuances On February 15, 2022, the Company granted 13,775 shares of restricted stock to two consultants that were engaged to provide investor relations services with a total fair market value on date of issuance of $98,078. On March 14, 2022, the Company granted 692 shares of restricted stock to a consultant that was engaged to provide investor relations services with a total fair market value on date of issuance of $4,500. On June 7, 2022, the Company granted 679 shares of restricted stock to a consultant that was engaged to provide investor relations services with a total fair market value on date of issuance of $4,500. On July 8, 2022, the Company granted 30,303 shares of restricted stock to a consultant that was engaged to provide investor relations services with a total fair market value on date of issuance of $150,000 and warrants to purchase 21,067 shares of Common Stock with an exercise price of $9.90 per share for a period of five years from the date of issuance. ​ Stock Compensation Expense ​ Total stock-based compensation for the three and six months ended June 30, 2022 was $1,016,690 and $1,728,248, respectively of which $171,653 and $845,037 was classified as research and development expense, respectively, and $845,037 and $1,435,545 was classified as general and administrative expense. Total stock-based compensation for the three and six months ended June 30, 2021 was $151,552 and $719,791, respectively, of which $35,763 and $209,465 was classified as research and development expense, respectively, and $115,789 and $510,326 was classified as general and administrative expense.

Common Stock Warrants

Common Stock Warrants	6 Months Ended
	Jun. 30, 2022
Common Stock Warrants
Common Stock Warrants	Note 8 – Common Stock Warrants: As of June 30, 2022, the Company had warrants outstanding consisting of the following: ​ ​ ​ ​ ​ Number ​ ​ of shares Warrants outstanding January 1, 2022 6,265,525 Warrants issued 10,300 Warrants exercised (65,000) Warrants expired ​ (1,049,368) Warrants outstanding June 30, 2022 5,161,457 ​ On January 3, 2022, pursuant to its advisory agreements, the Company issued warrants to purchase 10,300 shares of Common Stock, with an exercise price of $8.96 per share, for a period of five years from the issuance date. The Company used the Black-Scholes valuation model to calculate the value of these warrants issued to advisors during the six months ended June 30, 2022. The fair value of the warrants was estimated at the date of issuance using the following weighted average assumptions: Dividend yield 0%; Expected term five years; volatility based upon a blend of the Parent company’s and guideline company historical volatility 112.9%; and Risk-free interest rate of 1.37%. The total expense recorded during the year period was approximately $72,000. As of June 30, 2022, the weighted average exercise price and the weighted average remaining life of the total warrants were $13.34 per warrant and 3.7 years, respectively. The intrinsic value of the warrants as of June 30, 2022 was approximately $0.8 million. During the six months ended June 30, 2022, three affiliated warrant holders exercised 50,000 Series E Warrants to purchase 50,000 shares of Common Stock at $8.51 per share and one holder exercised 15,000 Series G Warrants to purchase 15,000 shares of Common Stock at $8.51 per share. Total cash proceeds from these warrant exercises was approximately $600,000.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events
Subsequent Events	Note 9 – Subsequent Events ​ See Note 5 and Note 7 above.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation: The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the unaudited condensed financial statements included herein contain all adjustments necessary to present fairly the Company’s financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the six months ended June 30, 2022 may not be indicative of results for the full year. These unaudited condensed financial statements should be read in conjunction with the audited condensed financial statements and the notes to those statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2022.
Use of Estimates	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management’s best judgment at a point in time and as such these estimates may ultimately differ from actual results. ​
Cash and Cash Equivalents and Concentration of Credit Risk	Cash and Cash Equivalents and Concentration of Credit Risk: The Company considers all highly liquid cash investments with an original maturity of three months or less when purchased to be cash equivalents. At June 30, 2022, the Company’s cash balances that exceed the current insured amounts under the Federal Deposit Insurance Corporation (“FDIC”) were approximately $1.0 million. In addition, approximately $27.6 million included in cash and cash equivalents were invested in a money market fund, which is not insured under the FDIC. ​
Fixed Assets	Fixed Assets: ​ Fixed assets are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the estimated useful life of the asset, which is deemed to be between three
Research and Development Costs	Research and Development Costs: All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE are expensed when incurred. Non-refundable advance payments for research and development are capitalized because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services, other than non-refundable advance payments as mentioned below for Worldwide Clinical Trials, at June 30, 2022 and December 31, 2021.
Income Taxes	Income Taxes: The Company accounts for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes under the “Separate return method.” Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions for accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company has determined that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is generally three years from the date of filing. The Company had federal and state net operating loss carryforwards for income tax purposes of approximately $84.4 million for the period from October 31, 2012 (inception) through June 30, 2022. The net operating loss carryforwards resulted in a deferred tax asset of approximately $17.7 million at June 30, 2022. Income tax effects of share-based payments are recognized in the financial statements for those awards that will normally result in tax deductions under existing tax law. The deferred tax asset is offset by a full valuation allowance. The Company may be subject to significant U.S. federal income tax-related liabilities with respect to the Spin-Off if there is a determination that the Spin-Off is taxable for U.S. federal income tax purposes. In connection with the Spin-Off, the Company believes that, among other things, the Spin-Off should qualify as a tax-free transaction for U.S. federal income tax purposes under Section 355 and Section 368(a)(1)(D) of the Internal Revenue Code of 1986 (the “Code”). If the conclusions of the tax opinions are not correct, or if the Spin-Off is otherwise ultimately determined to be a taxable transaction, the Company would be liable for U.S. federal income tax related liabilities. Pursuant to the Separation and Distribution Agreement and the Tax Matters Agreement, Neurotrope agreed to indemnify Synaptogenix for certain liabilities, and Synaptogenix agreed to indemnify Neurotrope for certain liabilities, in each case for uncapped amounts. Indemnities that Synaptogenix may be required to provide Neurotrope are not subject to any cap, may be significant and could negatively impact Synaptogenix’s business, particularly with respect to indemnities provided in the Tax Matters Agreement. Third parties could also seek to hold Synaptogenix responsible for any of the liabilities that Neurotrope has agreed to retain. Further, the indemnity from Neurotrope may not be sufficient to protect Synaptogenix against the full amount of such liabilities, and Neurotrope may not be able to fully satisfy its indemnification obligations. Moreover, even if Synaptogenix ultimately succeeds in recovering from Neurotrope any amounts for which Synaptogenix is held liable, Synaptogenix may be temporarily required to bear these losses. At June 30, 2022 and as of the date of financial statement issuance date, the Company does not have any indemnification liabilities. Under Section 382 of the Code, as amended, changes in the Company’s ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. In addition, the significant historical operating losses incurred by the Company may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. The Company believes that operating loss carryforwards are limited under Section 382 limitations although Section 382 studies have not been conducted to determine the actual limitations.
Expense Reimbursement for Grant Award	Expense Reimbursement for Grant Award: The Company reduces its research and development expenses by funding received or receivable from an NIH grant during the period that the expenses are incurred. The Company recognized grant related expense reductions during the three and six months ended June 30, 2022 of approximately $100,000 and $0, respectively, and $0 for the three and six months ended June 30, 2021, respectively. See Note 5, “ Clinical Trial Services Agreements Of the total $2.7 million available from the NIH grant, the Company has received the maximum reimbursements under the grant as of June 30, 2022.
Recent Accounting Pronouncements	Recent Accounting Pronouncements: In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, which reduces the number of accounting models for convertible instruments, amends diluted earnings per share calculations for convertible instruments and allows more contracts to qualify for equity classification. ASU 2020-06 will be effective for interim and annual periods beginning after December 15, 2021. Early adoption is permitted. The Company has evaluated the adoption of ASU 2020-06 and has concluded that it does not apply at this time. ​

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Stock Based Compensation
Schedule of stock outstanding under the plans	The following is a summary of stock option activity under the stock option plans for the six months ended June 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ Average ​ Aggregate ​ ​ ​ ​ Weighted- ​ Remaining ​ Intrinsic ​ ​ Number ​ Average ​ Contractual ​ Value ​ ​ of ​ Exercise ​ Term ​ (in ​ ​ Shares ​ Price ​ (Years) ​ millions) Options outstanding at January 1, 2022 123,850 ​ $ 9.84 9.00 ​ $ — Options granted 6,150 ​ $ 7.29 — ​ — Less options forfeited — ​ $ — — ​ — Less options expired/cancelled — ​ $ — — ​ — Less options exercised — ​ $ — — ​ — Options outstanding at June 30, 2022 130,000 ​ $ 9.72 8.60 ​ $ — Options exercisable at June 30, 2022 125,388 ​ $ 9.81 8.57 ​ $ —

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2022
Common Stock Warrants
Schedule of Common stock warrant activity	​ ​ ​ ​ ​ Number ​ ​ of shares Warrants outstanding January 1, 2022 6,265,525 Warrants issued 10,300 Warrants exercised (65,000) Warrants expired ​ (1,049,368) Warrants outstanding June 30, 2022 5,161,457

Organization, Business, Risks_2

Organization, Business, Risks and Uncertainties - Liquidity Uncertainties (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Organization, Business, Risks and Uncertainties
Common stock, par value	$ 0.0001	$ 0.0001
Cash and cash equivalents	$ 28,754,621	$ 34,213,989
Cash and cash equivalents expected amount at financial reporting date	$ 27,400,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jul. 23, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Summary Of Significant Accounting Policies [Line Items]
Cash balance of insured FDIC amount		$ 1,000,000		$ 1,000,000
Cash balance of uninsured amount		27,600,000		27,600,000
Capitalized research and development services		0		0		$ 0
Net operating loss carryforwards		84,400,000		84,400,000
Deferred tax assets of operating loss carryforwards		17,700,000		17,700,000
Expense related to grants		$ 100,000	$ 0	$ 0	$ 0
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life (years)				10 years
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life (years)				3 years
National Institutes of Health | 2020 Services Agreement
Summary Of Significant Accounting Policies [Line Items]
Amount of award received	$ 2,700,000			$ 2,700,000

Collaborative Agreements and _2

Collaborative Agreements and Commitments (Details)				3 Months Ended	6 Months Ended	12 Months Ended
	Aug. 05, 2021 USD ($)	Jan. 19, 2017 USD ($)	Jul. 14, 2014 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Annual license maintenance fee		$ 10,000
Commitment To Pay Fees		2,100,000
Number of Statements Entered Into Agreement				0	0	0	0
Stand Ford License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payment percentage					3%
Milestone payments made					$ 3,700,000
Payments for Royalties					0
Mt. Sinai License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments made					0
Payments for Royalties					0
Payable of milestone payments			$ 2,000,000
Additional milestone payments			1,500,000
Total services fees			180,000
Licensing fees			105,000
Development costs and patent fees			$ 75,000
Mt. Sinai License Agreement | Net sales up to $250 million
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payment percentage			2%
Threshold net sales			$ 250,000,000
Mt. Sinai License Agreement | Net sales over $250 million
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payment percentage			3%
Threshold net sales			$ 250,000,000
Agreements with BryoLogyx
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for Royalties					$ 1,000,000
Percentage of Gross Revenue				2%	2%
Other Income					$ 0
Nemours Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost on Trail and investigation new drug documentation expenses	$ 700,000
License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate amount paid		$ 70,000
Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payment percentage		1.50%
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty payment percentage		4.50%

Related Party Transactions (Det

Related Party Transactions (Details) - Consulting Agreement with SM Capital Management, LLC - USD ($)		3 Months Ended		6 Months Ended
	Aug. 04, 2016	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Contract payments, term	1 year
Annual consulting fee	$ 120,000
Monthly installment of annual consulting fee	$ 10,000
Consultancy Fees		$ 30,000	$ 60,000	$ 30,000	$ 60,000

Other Commitments_ (Details)

Other Commitments: (Details)												1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2022 USD ($)	Jan. 19, 2022 USD ($)	Jan. 01, 2022 USD ($)	Jul. 01, 2021 USD ($) $ / shares shares	Jan. 01, 2021 USD ($)	Dec. 07, 2020 USD ($)	Dec. 01, 2020 shares	Nov. 30, 2020 shares	Jul. 23, 2020 USD ($) item	Feb. 01, 2020 USD ($)	Jun. 01, 2019 USD ($)	Apr. 30, 2020 USD ($)	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2021 USD ($)	Feb. 10, 2022 USD ($)	Jan. 22, 2022 USD ($)	Jan. 03, 2022 $ / shares shares	Oct. 01, 2021 $ / shares shares	Apr. 30, 2021 USD ($)	Apr. 01, 2021 $ / shares shares	Feb. 16, 2021 $ / shares shares	Jan. 31, 2021
Other Commitments [Line Items]
Clinical trial expenses													$ 1,941,101	$ 986,280	$ 3,427,175	$ 2,138,060
Exercise price of warrants | $ / shares													$ 13.34		$ 13.34
Consulting Agreement with Katalyst Securities LLC [Member]
Other Commitments [Line Items]
Monthly installment of annual consulting fee			$ 10,000		$ 20,000
Consultancy fees													$ 30,000	93,687	$ 111,283	399,700
Payments for consulting per month											$ 25,000
Warrants term							5 years						5 years		5 years
Warrants to purchase shares of common stock | shares				4,500			4,500												4,500	4,500		4,500	25,000
Warrants term following the effective date							3 months
Exercise price of warrants | $ / shares				$ 9.76															$ 8.69	$ 9.30		$ 8.80	$ 11.46
Consulting Agreement with GP Nurmenkari, Inc [Member]
Other Commitments [Line Items]
Monthly installment of annual consulting fee			$ 10,000	$ 20,000	$ 12,000					$ 17,500
Consultancy fees													$ 30,000	$ 54,815	$ 120,320	189,148
Warrants to purchase shares of common stock | shares				5,800				2,500											5,800	5,800		2,500	10,000
Warrants term following the effective date								3 months
Exercise price of warrants | $ / shares				$ 9.76															$ 8.69	$ 9.30		$ 8.80	$ 11.46
2020 Services Agreement
Other Commitments [Line Items]
Target enrollment of study subjects | item									100
Amount funded against the total trial cost																	$ 1,000,000	$ 1,400,000
Total estimated budget for the services									$ 12,000,000
Threshold period of prior written notice to terminate agreement									60 days
Clinical trial expenses															1,200,000	$ 2,500,000
WCT prepayments included as a prepaid expense and other current assets													281,000		281,000
WCT payments included in accounts payable													414,000		414,000
2020 Services Agreement | National Institutes of Health
Other Commitments [Line Items]
Total estimated budget for the services									$ 9,300,000
Amount of award received									2,700,000						2,700,000
Funding received												$ 1,000,000
Funding receivable in year two																					$ 1,700,000
Clinical trial expenses									$ 9,400,000						9,400,000
2022 Services Agreement
Other Commitments [Line Items]
Total estimated budget for the services													2,000,000		$ 2,000,000
Threshold period of prior written notice to terminate agreement															30 days
Employment agreement with Alan J. Tuchman, M.D
Other Commitments [Line Items]
Initial annual base salary						$ 222,000
Annual discretionary bonus payable (as a percent)						50%
Options granted to purchase shares of common stock as a percent of Company's outstanding shares of common stock immediately following the Spin-Off																								1%
Term of the agreement						1 year
Extension periods of the agreement						6 months
Work order to Cyprotex US, LLC
Other Commitments [Line Items]
Consultancy fees		$ 165,455											$ 169,000		$ 177,000
Statement Of Work With Charles River Laboratories, Inc
Other Commitments [Line Items]
Threshold period of prior written notice to terminate agreement	30 days
Consultancy fees	$ 197,600

Stockholders' Equity (Details)

Stockholders' Equity (Details)	6 Months Ended
	Jun. 30, 2022 Vote $ / shares shares	Dec. 31, 2021 $ / shares shares
Stockholders' Equity
Common stock, shares authorized	150,000,000	150,000,000
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001
Votes per share of common stock | Vote	1

Stockholders' Equity - January

Stockholders' Equity - January 2021 June 2021 Private Placement (Details)						6 Months Ended
	Jun. 14, 2021 USD ($) $ / shares shares	May 19, 2021	Jan. 21, 2021 USD ($) $ / shares shares	Jan. 19, 2021 USD ($) $ / shares shares	Jan. 13, 2021 shares	Jun. 30, 2022 $ / shares shares	Dec. 31, 2021 $ / shares
Class of Stock [Line Items]
Warrants exercise price | $ / shares						$ 13.34
Preferred stock, par value (in dollars per share) | $ / shares						$ 0.0001	$ 0.0001
Reverse Stock Split, conversion ratio		0.25
Minimum
Class of Stock [Line Items]
Reverse Stock Split, conversion ratio						1.5
Maximum
Class of Stock [Line Items]
Reverse Stock Split, conversion ratio						20
Placement Agents
Class of Stock [Line Items]
Common share issuable upon exercise of warrants | shares	152,378
Warrants exercise price | $ / shares	$ 7.547
Warrants exercise period	5 years
Percentage of offering fees in cash	10%
Number of shares issued upon exchange | shares	152,378
Percentage of offering fees in warrants	10%
Percentage of offering fees on aggregate price of warrant exercise	10%
Period within which future financing should be consummated	18 months
Securities Purchase Agreements
Class of Stock [Line Items]
Warrants exercise period	5 years
Combined purchase price of common stock and warrants | $ / shares	$ 7.547		$ 6
Gross proceeds in offering | $	$ 12,500,000		$ 14,000,000
Net proceeds in offering | $	$ 11,200,000		$ 12,500,000
Securities Purchase Agreements | Placement Agents
Class of Stock [Line Items]
Common share issuable upon exercise of warrants | shares			233,391
Warrants exercise price | $ / shares			$ 6.90
Warrants exercise period			5 years
Percentage of offering fees in cash			10%
Number of shares issued upon exchange | shares			233,391
Percentage of offering fees in warrants			10%
Shareholder Rights Plan
Class of Stock [Line Items]
Number of preferred share purchase right for each outstanding share of Common Stock by means of dividend | shares					1
Minimum acquisition percentage of outstanding common stock to exercise rights					15
Discount available to right holders to purchase common stock upon acquisition of minimum shareholding by acquiring person					50%
Number of common shares for each right | shares					1
Rights Agreement
Class of Stock [Line Items]
Number of One-Thousandth share of Series A Preferred stock Issued In Right | shares				1
Preferred stock, par value (in dollars per share) | $ / shares				$ 0.001
Purchase price of right | $				20
Prefunded warrants | Securities Purchase Agreements
Class of Stock [Line Items]
Aggregate number of shares authorized to issue under purchase agreement | shares	1,653,281		2,333,884
Share price | $ / shares			$ 0.04
Warrants exercise price | $ / shares	$ 0.01
Series E Warrants
Class of Stock [Line Items]
Common share issuable upon exercise of warrants | shares						50,000
Warrants exercise price | $ / shares						$ 8.51
Series E Warrants | Securities Purchase Agreements
Class of Stock [Line Items]
Common share issuable upon exercise of warrants | shares			2,333,908
Warrants exercise price | $ / shares			$ 8.51
Warrants exercise period			12 months
Series G Warrants
Class of Stock [Line Items]
Common share issuable upon exercise of warrants | shares						15,000
Warrants exercise price | $ / shares						$ 8.51
Potential fee | $	$ 1,400,000
Series G Warrants | Securities Purchase Agreements
Class of Stock [Line Items]
Aggregate number of shares authorized to issue under purchase agreement | shares	1,653,281
Warrants exercise price | $ / shares	$ 8.51
Series F Warrants | Securities Purchase Agreements
Class of Stock [Line Items]
Aggregate number of shares authorized to issue under purchase agreement | shares			2,333,908
Share price | $ / shares			$ 6.90
Warrants exercise period			5 years

Stock Based Compensation (Detai

Stock Based Compensation (Details)

3 Months Ended

6 Months Ended

Jul. 08, 2022 USD ($) $ / shares shares

Jun. 07, 2022 USD ($) shares

May 16, 2022

Mar. 14, 2022 USD ($) shares

Feb. 16, 2022 $ / shares shares

Feb. 15, 2022 USD ($) shares

Jul. 13, 2021 employee director shares

Mar. 12, 2021 shares

Jun. 30, 2022 USD ($) $ / shares

Jun. 30, 2021 USD ($)

Jun. 30, 2022 USD ($) $ / shares shares

Jun. 30, 2021 USD ($)

Apr. 07, 2021 shares

Dec. 07, 2020 shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of securities available for grant

625,000

250,000

Number of options granted

6,150

Stock options expense | $

$ 11,544

$ 151,552

$ 47,918

$ 719,791

Exercise price | $ / shares

$ 7.29

Total unrecognized compensation costs | $

$ 16,900

$ 16,900

Total unrecognized compensation costs expected to be recognized over a weighted average period

7 months 17 days

Warrants exercise price | $ / shares

$ 13.34

$ 13.34

2020 Equity Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options expense | $

$ 1,016,690

151,552

$ 1,728,248

719,791

2020 Equity Incentive Plan | Research and development

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options expense | $

171,653

35,763

845,037

209,465

2020 Equity Incentive Plan | General and administrative

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options expense | $

845,037

$ 115,789

1,435,545

$ 510,326

2020 Equity Incentive Plan | Chief Executive Officer

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

6,150

Expected term

10 years

Exercise price of stock options | $ / shares

$ 7.29

Vesting percentage

25%

Vesting period

1 year

RSU's

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

495,000

Stock options expense | $

1,005,146

1,680,331

Vesting percentage

100%

Number of director | director

7

Number of executive directors | director

2

Total unrecognized compensation costs | $

$ 885,000

$ 885,000

Total unrecognized compensation costs expected to be recognized over a weighted average period

5 months 8 days

Grant date fair value of RSU's issued (per share) | $ / shares

$ 9.75

Grant date fair value of RSU's issued | $

$ 4,800,000

Restricted Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares granted

679

692

13,775

Fair market value of shares issued | $

$ 4,500

$ 4,500

$ 98,078

Nonemployee directors | Director Compensation Policy

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of securities available for grant

1,500

Nonemployee directors | RSU's

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

425,000

Newly appointed director | Director Compensation Policy

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of securities available for grant

1,200

Stock option grant authorized for service on a committee of the Board of Directors

300

Employee | RSU's

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

10,000

Entity number of employees | employee

2

CFO | RSU's

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted

60,000

Subsequent events | Restricted Stock

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares granted

30,303

Fair market value of shares issued | $

$ 150,000

Warrants to purchase shares of common stock

21,067

Warrants exercise price | $ / shares

$ 9.90

Warrants term

5 years

Date of grant | Newly appointed director | Director Compensation Policy

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

50%

First anniversary from Start Date | RSU's

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

100%

First anniversary from Start Date | Newly appointed director | Director Compensation Policy

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

25%

Second anniversary from Start Date | Newly appointed director | Director Compensation Policy

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting percentage

25%

Stock Based Compensation - Stoc

Stock Based Compensation - Stock option activity under the stock option plans (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Number of Shares
Options outstanding at the beginning	123,850
Options granted	6,150
Options outstanding at the end	130,000	123,850
Options exercisable at the end	125,388
Weighted-Average Exercise Price
Options outstanding at the beginning (in dollars per share)	$ 9.84
Options granted (in dollars per share)	7.29
Options outstanding at the end (in dollars per share)	9.72	$ 9.84
Options exercisable at the end (in dollars per share)	$ 9.81
Weighted-Average Remaining Contractual Term (Years)
Options outstanding at the end (in years)	8 years 7 months 6 days	9 years
Options exercisable at the end (in years)	8 years 6 months 25 days
Aggregate Intrinsic Value
Options outstanding at the end (in dollars)	$ 0	$ 0
Options exercisable at the end (in dollars)	$ 0

Common Stock Warrants - Common

Common Stock Warrants - Common stock warrant activity (Details)	6 Months Ended
	Jun. 30, 2022 shares
Common Stock Warrants
Warrants outstanding January 1, 2022	6,265,525
Warrants issued	10,300
Warrants exercised	(65,000)
Warrants expired	(1,049,368)
Warrants outstanding June 30, 2022	5,161,457

Common Stock Warrants - Additio

Common Stock Warrants - Additional Information (Details)	6 Months Ended
	Jun. 30, 2022 USD ($) item $ / shares shares	Jun. 30, 2021 USD ($)	Jan. 03, 2022 $ / shares shares
Warrants exercise price | $ / shares	$ 13.34
Weighted average remaining life of warrants	3 years 8 months 12 days
Intrinsic value of the warrants | $	$ 800,000
Proceeds from warrant exercises | $	553,150	$ 7,582,276
Warrant
Proceeds from warrant exercises | $	$ 600,000
Series G Warrants
Number of warrant holders who exercised their warrants | item	1
Warrants outstanding | shares	15,000
Warrants exercise price | $ / shares	$ 8.51
Warrants to purchase shares of common stock | shares	15,000
Series E Warrants
Number of warrant holders who exercised their warrants | item	3
Warrants outstanding | shares	50,000
Warrants exercise price | $ / shares	$ 8.51
Warrants to purchase shares of common stock | shares	50,000
Dividend yield
Warrants, measurement input	0
Expected term
Warrants, measurement input | $	5
Volatility
Warrants, measurement input	112.9
Risk-free interest rate
Warrants, measurement input	1.37
Advisory Agreements [Member]
Warrants exercise price | $ / shares			$ 8.96
Warrants to purchase shares of common stock | shares			10,300
Warrants term			5 years
Total expense | $	$ 72,000